# Vanderbilt Center for Diabetes Translation Research

> **NIH NIH P30** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2020 · $661,879

## Abstract

Center Overview Project Summary/Abstract
Clinical trials have established that glycemic control and cardiovascular risk factor modification can reduce the
risk of complications of type 1 and type 2 diabetes. In addition, behavioral strategies have been shown to delay
or prevent the development of type 2 diabetes in individuals at high risk for diabetes. Despite the clarity of
evidence, many individuals with diabetes do not meet the recommended goals of diabetes care. There is an
unequivocal gap between evidence and real-world diabetes prevention and treatment, and this gap is particular
evident in many racial and ethnic minorities.
Investigators at the Vanderbilt University Medical Center and Meharry Medical College propose a renewal to
our Center for Diabetes Translation Research ( https://labnodes.vanderbilt.edu/cdtr ) to bridge this gap by
building on our success in type II translation research. This renewal proposal is based on a highly productive
initial five years and a plan for the next cycle that maintains continuity with our excellent leadership while
introducing change to reflect the changing needs of our research base. During the past five years our research
base has significantly enlarged (from 23 to 38), been well funded (annual direct costs from NIDDK alone of
nearly five million), and published important manuscripts (136 cited). Our P&F program has been extremely
successful (8 investigators funded for 30K/year for two years) in that four investigators have already received
either a K award or a DP3 award and a fifth awardee has secured a RO1. We believe our P&F program, owing
to the ability to leverage institutional matching funds and the ability to extend over two years, has been one of
the most successful aspects of the Center. Our enrichment program is extensive and includes collaborations
with multiple entities across campus.
We propose to build on the excellence of the past five years by maintaining continuity in our core structure and
leadership while introducing a new core (Behavioral Intervention Technologies and Services Core) and leader
(Chandra Osborn, Ph.D.) to reflect the expanding research base that utilizes technology for behavioral
interventions. We maintain a focus on health disparities through our long standing relationship with Meharry
Medical College and build on that foundation by introducing a new leader (Consuelo Wilkins, M.D.) to lead our
enrichment core. Dr. Wilkins leads the Meharry-Vanderbilt Alliance (https://medschool.vanderbilt.edu/meharry-
vanderbilt/) which explicity promotes collaboration between our two institutions to promote clinical and
community-engaged collaboration, education and research. These additions build on our theme of reducing
health disparities while expanding on our efforts to advance knowledge in behavioral intervention technologies.

## Key facts

- **NIH application ID:** 10016252
- **Project number:** 5P30DK092986-11
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** TOM A ELASY
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $661,879
- **Award type:** 5
- **Project period:** 2011-09-01 → 2022-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10016252

## Citation

> US National Institutes of Health, RePORTER application 10016252, Vanderbilt Center for Diabetes Translation Research (5P30DK092986-11). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10016252. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*